![](https://thepharmadata.com/wp-content/uploads/2024/07/Pharmaceutical-Leader-Kare-Schultz-Appointed-to-Hims-Hers-Board.webp)
Hims & Hers Health, a leading health and wellness platform, has announced the appointment of Kåre Schultz to its Board of Directors. Schultz, known for his extensive global expertise in healthcare and pharmaceuticals, brings decades of experience from his roles at Teva Pharmaceutical Industries, Lundbeck, and Novo Nordisk. His notable achievements include over 25 years at Novo Nordisk, where he was pivotal in establishing the company as a leader in diabetes care, and his leadership as CEO of Teva, where he refocused the company on generics and specialty medicines. Schultz also served as CEO of Lundbeck, enhancing its standing in the pharmaceutical sector.
Andrew Dudum, CEO and co-founder of Hims & Hers, expressed enthusiasm about Schultz’s appointment, stating, “We are at a pivotal moment in healthcare, with the chance to make transformative treatments widely accessible. Kåre’s extensive experience will greatly benefit us as we integrate clinical excellence, healthcare, and technology to redefine health and wellness for our customers. We are excited to leverage his insight and leadership as we expand our reach.”
Schultz shared his excitement about joining Hims & Hers, stating, “Hims & Hers is uniquely positioned to revolutionize the healthcare industry. Throughout my career, I have not seen a company so adept at using modern tools to dismantle barriers and transform access to essential health solutions. I am eager to contribute to this groundbreaking journey.”
Schultz joins a distinguished Board of Directors at Hims & Hers, which includes former Cleveland Clinic CEO Dr. Toby Cosgrove; tech industry leader Christopher Payne; US regulatory and foreign policy expert Anja Manuel; former Walgreens CMO and current Hims & Hers CMO Patrick Carroll; former Netflix CFO David Wells; consumer retail expert Christiane Pendarvis; and former Nike and Sony marketing executive Andrea Perez.